SCHEMBL6520766

SCHEMBL6520766

O=C(C=Cc1ccc(Cl)c(Cl)c1)Nc1ccccc1C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 7/20 0.74
TRPM2 O94759 2/20 0.67
LTB4R Q15722 2/20 0.67
TRPM8 Q7Z2W7 3/20 0.66
MEN1 O00255 6/20 0.65
KMT2A Q03164 6/20 0.65
NPC1 O15118 5/20 0.65
RAB9A P51151 5/20 0.65
SMN1; SMN2 Q16637 5/20 0.65
ALDH1A1 P00352 4/20 0.65
HPGD P15428 3/20 0.65
CYP3A4 P08684 3/20 0.65
KDM4E B2RXH2 3/20 0.65
TP53 P04637 2/20 0.65
HIF1A Q16665 2/20 0.65
NPSR1 Q6W5P4 2/20 0.65
CYP1A2 P05177 2/20 0.65
CYP2C19 P33261 2/20 0.65
NFKB1 P19838 2/20 0.65
CYP2C9 P11712 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6520762 1.00 TRPA1 (0.74) TRPA1TRPM2LTB4RTRPM8MEN1
SCHEMBL5147597 0.87 TRPM2 (0.64) TRPA1TRPM2LTB4RTRPM8MEN1
SCHEMBL5147601 0.87 TRPM2 (0.64) TRPA1TRPM2LTB4RTRPM8MEN1
SCHEMBL8060447 0.86 TRPA1 (0.61) TRPA1TRPM2LTB4RMEN1KMT2A
SCHEMBL8060450 0.86 TRPA1 (0.61) TRPA1TRPM2LTB4RMEN1KMT2A
SCHEMBL3274563 0.86 KCNK2 (0.62) TRPA1TRPM2LTB4RMEN1KMT2A
SCHEMBL3274559 0.86 KCNK2 (0.62) TRPA1TRPM2LTB4RMEN1KMT2A
SCHEMBL2779614 0.86 MEN1 (0.81) TRPA1TRPM2LTB4RTRPM8MEN1
SCHEMBL2779612 0.86 MEN1 (0.81) TRPA1TRPM2LTB4RTRPM8MEN1
SCHEMBL2779997 0.85 TRPA1 (1.00) TRPA1TRPM2LTB4RTRPM8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110054034-A1 METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS GRAND VALLEY STATE UNIVERSITY 2011-03-03 US claimed
US-20110054034-A1 METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS GRAND VALLEY STATE UNIVERSITY 2011-03-03 US disclosed
US-6127392-A A MUSCLE RELAXANT FOR TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION VIA POTASSIUM CHANNEL AND CHLORIDE CHANNEL MODULATION; INOTROPIC AGENT AMERICAN HOME PRODUCTS CORPORATION (US) 2000-10-03 US disclosed
EP-1003712-A1 ANTHRANILIC ACID ANALOGS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-05-31 EP disclosed
US-6046239-A USED IN THE TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION, VIA POTASSIUM CHANNEL AND CHLORIDE CHANNEL MODULATION SUCH AS URINARY INCONTINENCE, ASTHMA, ANGINA, PREMATURE LABOR, CONGESTIVE HEART FAILURE AMERICAN HOME PRODUCTS CORPORATION (US) 2000-04-04 US disclosed
WO-1999007669-A1 ANTHRANILIC ACID ANALOGS AMERICAN HOME PRODUCTS CORPORATION (US) 1999-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054034-A1 METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS NAAA, ELANE, APEH TRPA1 1639/4885TRPM2 2644/4885LTB4R 1900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.